Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

04. Januar 2016 16:05 ET | Quelle: Repros Therapeutics Inc.

Repros Updates Enclomiphene Program

Repros expects to meet with FDA to discuss “Complete Response Letter” for enclomiphene NDA during February 2016Marketing Authorization Application (MAA) for enclomiphene planned for submission in...
21. Dezember 2015 16:05 ET | Quelle: Repros Therapeutics Inc.

Repros Updates Proellex® Program

Topline results after first four months of treatment from all three Proellex® trials expected to be available by end of Q3’16Screening for low dose study for oral Proellex® for uterine fibroids...
01. Dezember 2015 09:50 ET | Quelle: Repros Therapeutics Inc.

Repros Therapeutics Receives Complete Response Letter From FDA for Enclomiphene

THE WOODLANDS, Texas, Dec. 1, 2015 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that it has received a Complete Response Letter from the U.S. Food and Drug...
12. November 2015 16:05 ET | Quelle: Repros Therapeutics Inc.

Repros Therapeutics Completes Randomization of Phase 2b Study of Vaginal Proellex(R) in Women With Symptomatic Uterine Fibroid Bleeding

THE WOODLANDS, Texas, Nov. 12, 2015 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced it has completed randomization for its Phase 2b study of Proellex® in the...
09. November 2015 09:15 ET | Quelle: Repros Therapeutics Inc.

Repros Therapeutics Inc.(R) Reports Third Quarter 2015 Financial Results

THE WOODLANDS, Texas, Nov. 9, 2015 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced financial results for the third quarter ended September 30, 2015. Financial...
29. Oktober 2015 15:12 ET | Quelle: Repros Therapeutics Inc.

Repros Therapeutics Announces Cancellation of FDA Advisory Committee Meeting to Review Enclomiphene for the Treatment of Secondary Hypogonadism

THE WOODLANDS, Texas, Oct. 29, 2015 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that the Division of Bone, Reproductive and Urologic Products of the U.S. Food and...
10. August 2015 09:15 ET | Quelle: Repros Therapeutics Inc.

Repros Therapeutics Inc.(R) Reports Second Quarter 2015 Financial Results

THE WOODLANDS, Texas, Aug. 10, 2015 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced financial results for the second quarter ended June 30, 2015. Financial Results...
08. Juni 2015 17:48 ET | Quelle: Repros Therapeutics Inc.

Repros Announces Date of FDA Advisory Committee Review of NDA

THE WOODLANDS, Texas, June 8, 2015 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that the Division of Bone, Reproductive and Urologic Products of the U.S. Food and...
07. Mai 2015 09:15 ET | Quelle: Repros Therapeutics Inc.

Repros Therapeutics Inc.(R) Reports First Quarter 2015 Financial Results

THE WOODLANDS, Texas, May 7, 2015 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced financial results for the first quarter ended March 31, 2015. Financial Results...
15. April 2015 16:01 ET | Quelle: Repros Therapeutics Inc.

Repros Announces November 30, 2015 PDUFA Goal Date for New Drug Application

THE WOODLANDS, Texas, April 15, 2015 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that the U.S. Food and Drug Administration (FDA) assigned a Prescription Drug User...

Vorherige Seite